by Raynovich Rod | Oct 31, 2016 | Biopharmaceuticals
Biotech Meltdown: Numbers Don’t Mean Much Until We See New Product Growth We are almost through the earnings season and despite good results most biotech stocks tanked again today.The reason you know well by now-expectations for earnings and top line growth have...
by Raynovich Rod | Oct 26, 2016 | Biopharmaceuticals, Macro
Update-3… 10/28 9:30 am… No Relief From Earnings- Biotech Stocks Get Crushed By More Pricing Commentary on Earnings Calls Amgen (AMGN) down 11% on pipeline, revenue growth, Enbrel pricing concerns despite beat. Softer pricing environment from McKesson...
by Raynovich Rod | Oct 5, 2016 | Biopharmaceuticals
Green Tape Today Shows Resilience– 10/10/16 ESMO Cancer Congress 4%+ Up movers: AGIO ARIA BLUE CLVS LGND PBYI TSRO etc. XBI up 2.39% More Bad Clinical News for Biotech:ALNY,CLVS The XBI lost 3.2% for the week to $64.15 taking a hit from Alnylam (ALNY) downdraft...
by Raynovich Rod | Sep 22, 2016 | Biopharmaceuticals
Biotech ETFs Are Having A Strong Quarter and Offer Good Investment Options On July 20 we did a review of active funds vs biotech ETFs in the biotechnology/life science sector just after the BREXIT lows. At that time biotech ETFs and broadly diversified funds beat the...
by Raynovich Rod | Sep 20, 2016 | Biopharmaceuticals
Update-1…FED Goes on Hold with Rate Increase Likely by Year End Three on FOMC dissented wanting a rate hike this round. Market immediately rallied with NASDAQ up 1.03% at close; S&P and Dow also rally. Biotechs like low i rates:IBB up 0.62% to $297, XBI up...
by Raynovich Rod | Sep 15, 2016 | Biopharmaceuticals
Biopharma Stocks Breeze through ‘Quadruple Witching Day”…9/16 Healthcare stocks (XLV) were one of the leading sectors on a down day up a tiny bit to $72. The IBB held, up 0.57% to the $291 mark and up 4.75% for the week. The more volatile XBI was a...
by Raynovich Rod | Aug 31, 2016 | Biopharmaceuticals
Update-2… 945 am EDT…Biotechs Hold Support IBB up 1.55% to $285 holding support at $280; XBI up 2.99% to $61.95 holding support at $60. Update-1…More Fallout from Mylan (MYL) EpiPen Drug Pricing MYL stock was down over 4% today on news that the...
by Raynovich Rod | Aug 28, 2016 | Biopharmaceuticals
Update-1… IBB Trying to hold the $280 line after media bashing of EpiPen Pricing- now they have a generic EpiPen for half the price! Biotech outflows are a concern (-$184M) Gilead Sciences (GILD) down 2.89% on new potential competition from GlaxoSmithK (GSK) HIV...
by Raynovich Rod | Aug 23, 2016 | Biopharmaceuticals
Update-1 After Close 8/24 IBB at 286.23 XBI down 4.34% XLV down 1.54%, NASDAQ down 0.81% Early Afternoon Reversal Kills Biotech Rally In Heavy Trading But Mylan is not a biotech Company?? The broad based rally in biotech stocks faded around 1P EDT Wednesday as...
by Raynovich Rod | Aug 10, 2016 | Biopharmaceuticals, Clinical Diagnostics and Tools
Update August 15 : Biotech Leads But Healthcare Sector Lags IBB up 0.92% to $295, XBI up 1.33% to $63.35, XLV up 0.17% to $74.91 The tape was pretty decent despite a quiet day with ALXN up 1.97%, AMGN up 1.49% and CELG up 1.08%. Mid-caps also found bids: ALKS up...
